Human Immunodeficiency Virus (HIV) infection Human immunodeficiency virus (HIV) infection Known human immunodeficiency virus (HIV) infection, solid organ transplantation, or other immunosuppressed state (for treatment phase) Immunosuppressed status due to known human immunodeficiency virus (HIV) infection, severe uncontrolled diabetes, concurrent hematological malignancy, or other comorbidities Has a diagnosis of immunodeficiency including subjects infected with human immunodeficiency virus (HIV) Procurement: Patients with active human immunodeficiency virus (HIV) infection (can be pending at this time) Human immunodeficiency virus (HIV) infection Infection with human immunodeficiency virus (HIV) Patients may not have diagnosed human immunodeficiency virus (HIV) Human Immunodeficiency Virus infection at screening. Human immunodeficiency virus (HIV) Human immunodeficiency virus (HIV /) Human immunodeficiency virus (HIV) Human Immunodeficiency Virus (HIV) infection Human immunodeficiency virus (HIV) infection. Subjects must not have a confirmed human immunodeficiency virus (HIV) infection. Human immunodeficiency virus (HIV) infection. Active human immunodeficiency virus (HIV) infection Uncontrolled human immunodeficiency virus (HIV) infection Uncontrolled human immunodeficiency virus (HIV) Participants that are cancer survivors or those with human immunodeficiency virus (HIV) will not be excluded from the study Human immunodeficiency virus (HIV) infection Documented human immunodeficiency virus (HIV)-infection Infection with human immunodeficiency virus (HIV) Human immunodeficiency virus (HIV) infection Human immunodeficiency virus (HIV) infection Diagnosed immunodeficiency, eg, human immunodeficiency virus (HIV) Patients with human immunodeficiency virus (HIV) are not permitted to enroll Immunosuppressive disease or human immunodeficiency virus infection Patients with human immunodeficiency virus (HIV) infection are excluded from the study Human immunodeficiency virus (HIV) infection with CD count < Not be in an immunosuppressed state (e.g. human immunodeficiency virus [HIV], use of chronic steroids) Human immunodeficiency virus (HIV) infection Human immunodeficiency virus (HIV) infection Human immunodeficiency virus (HIV) infection Human immunodeficiency virus (HIV) infection Human immunodeficiency virus (HIV) infection Research participants who have confirmed human immunodeficiency virus (HIV) within weeks of screening Previous therapy with a human immunodeficiency virus (HIV) protease inhibitor Human immunodeficiency virus (HIV) infection Human immunodeficiency virus (HIV) infection Human immunodeficiency virus (HIV) infection RECIPIENT: Human immunodeficiency virus (HIV) infection Human immunodeficiency virus (HIV) infection Human immunodeficiency virus (HIV) infection Patients must have an expected survival without treatment of > days and must be free of major infection including human immunodeficiency virus (HIV) DONOR: Infection with human immunodeficiency virus (HIV) Human immunodeficiency virus (HIV) infection Human immunodeficiency virus (HIV)+ serology Human immunodeficiency virus (HIV) infection Autoimmune disease requiring therapy, prior organ transplant, or human immunodeficiency virus (HIV) infection Human immunodeficiency virus (HIV) infection Subjects cannot have an active immunodeficiency disorder, e.g. human immunodeficiency virus (HIV) Human immunodeficiency virus (HIV) infection Confirmed human immunodeficiency virus (HIV) infection. Active systemic infection requiring treatment, including any human immunodeficiency virus (HIV) infection or toxoplasmosis No human immunodeficiency virus (HIV) infection; patients with immune dysfunction are at a significantly higher risk of toxicities from intensive immunosuppressive therapies Patients with human immunodeficiency virus (HIV) infection are ineligible Human immunodeficiency virus (HIV) infection Immunodeficiency states including human immunodeficiency virus (HIV) infection DONOR: Infection with human immunodeficiency virus (HIV) Human immunodeficiency virus (HIV) infection. Human immunodeficiency virus (HIV)-infection Infection with human immunodeficiency virus (HIV) No human immunodeficiency virus (HIV) disease; patients with immune dysfunction are at a significantly higher risk of infection from intensive immunosuppressive therapies Human immunodeficiency virus infection. Human immunodeficiency virus (HIV) antibody Patient Human Immunodeficiency Virus (HIV) infection Human Immunodeficiency Virus (HIV) infection No infection with human immunodeficiency virus (HIV) Patients with active and uncontrolled human immunodeficiency virus (HIV) infection will be excluded; however, patients with well controlled HIV infection will be considered Human immunodeficiency virus (HIV) infection No uncontrolled infection\r\n* Note: infection is permitted if there is evidence of response to medication; eligibility of human immunodeficiency virus (HIV) infected patients will be determined on a case-by-case basis Documented human immunodeficiency virus (HIV) infection Human immunodeficiency virus (HIV) Human immunodeficiency virus (HIV) Human immunodeficiency virus (HIV) Uncontrolled human immunodeficiency virus (HIV) Human immunodeficiency virus (HIV) infection or immunodeficiency disorders, either primary or acquired Human immunodeficiency virus (HIV) infection Human immunodeficiency virus (HIV) infection Human immunodeficiency virus (HIV) infection Anti-human immunodeficiency virus (HIV) Antibody (alpha-HIV ) Infection with human immunodeficiency virus (HIV) Patients with human immunodeficiency virus (HIV) Human immunodeficiency virus infection Human immunodeficiency virus (HIV) infection Human Immunodeficiency Virus (HIV) infection Human immunodeficiency virus (HIV) associated lymphoma Evidence of human immunodeficiency virus (HIV) infection Active cardiac disease and human immunodeficiency virus (HIV) infection No uncontrolled infection\r\n* Note: Infection is permitted if there is evidence of response to medication; eligibility of human immunodeficiency virus (HIV) infected patients will be determined on a case-by-case basis Human Immunodeficiency Virus (HIV) infection. Patients with human immunodeficiency virus (HIV) Human immunodeficiency virus (HIV) infection Patient has significant comorbidities (e.g., human immunodeficiency virus [HIV], transplant), or another illness that may require hospitalization No uncontrolled infection\r\n* Note: infection is permitted if there is evidence of response to medication; eligibility of human immunodeficiency virus (HIV) infected patients will be determined on a case?by?case basis Human immunodeficiency virus (HIV) infection Uncontrolled human immunodeficiency virus (HIV), CD count < Patients with human immunodeficiency virus (HIV) are excluded Presence of active infection including human immunodeficiency virus (HIV) Human immunodeficiency virus (HIV) infection Patients who receive maraviroc for the treatment of human immunodeficiency virus (HIV) infection Patients must be human immunodeficiency virus (HIV) non-reactive Human immunodeficiency virus (HIV) infection Human immunodeficiency virus (HIV) infection No human immunodeficiency virus (HIV) disease (patients with immune dysfunction are at a significantly higher risk of infection from intensive immunosuppressive therapies) Documented human immunodeficiency virus (HIV) infection, genital warts, chancroid, or pelvic inflammatory disease that will require long term treatment Patients with human immunodeficiency virus (HIV) infection Human immunodeficiency virus (HIV) infection